Drug intelligence / Profile preview

HTD1804

Development stage: Unknown
Lead developer: HighTide Therapeutics

Overview

HTD1804 is a clinical-stage drug candidate being developed by HighTide Therapeutics for the treatment of obesity. As of 2025, the candidate is in Phase 1 clinical development. While the specific biological target and molecular modality remain undisclosed by the developer, HTD1804 is part of HighTide's broader pipeline focused on cardiovascular-kidney-metabolic (CKM) and digestive diseases. It represents an expansion of the company's metabolic portfolio alongside other candidates like HTD1801 and HTF1037.

Beyond the preview

Go deeper on HTD1804.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HTD1804.

Explore the full profile